Pulse Biosciences Partners with Clayman Thyroid Center for Commercial Launch and Clinical Data
PLSE has more than doubled off its 52-week low of $12.56.
Summary
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center, a high-volume thyroid surgery center in Tampa. The center is now treating patients with the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules, making it the only site in the Tampa Bay area offering the technology. The collaboration also includes real-world outcomes data collection and formal clinical studies to build evidence for the Vybrance System. This follows the September completion of enrollment in the PRECISE-BTN study and the October NANOPULSE-AF enrollment milestone, signaling continued commercial and clinical momentum. The partnership expands controlled market development and adds a key reference center with significant referral patterns.
At the time of this announcement, PLSE was trading at $53.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $12.56 to $58.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.